Vaccine Info

Whole-Viron SARS-CoV-2 Vaccine

Whole-Viron Vaccine Description

Whole-virion vaccines use either artificially weakened viruses that are unable to cause disease, or viruses that have already been killed (inactivated). Preclinical studies of the vaccine have shown the formation of a persistent immune response.

The Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products at the Russian Academy of Sciences has filed an application for a Russian health ministry’s permit for clinical tests of its anti-coronavirus vaccine.

'A clinical trial will be launched in the near future at the medical institutions of Kirov, St. Petersburg, and Novosibirsk. The expected number of participants is more than 3,000. After vaccination, volunteers will be isolated in a hospital for 16 days, where their condition will be monitored by doctors,' added a website statement.

"Preclinical tests of the whole-virion vaccine have proved that a sustainable immune response is developed. After clinical trials are successfully over, mass production of our vaccine can be organized already in November. It will be a liquid vaccine to be inoculated two times with a 14-day interval," he added.

On October 6, 2020, as part of the first phase, 15 volunteers were vaccinated, there were no serious complications or side effects, all volunteers feel well, and on October 19 the second phase starts, within which another 285 volunteers will be immunized. Clinical trials of this vaccine are expected to be completed by December, in which case another will join the first two vaccines.

Whole-Viron Vaccine Indication

This vaccine candidate is indicated to prevent COVID-19 disease caused by the SARS-CoV-2 virus.

Whole-Virion Vaccine News

October 14, 2020 - Russian President Vladimir Putin said that the vaccine developed by the Vektor center had received a registration certificate.

August 23, 2020 - The Federal Research Center for Research and Development of Immunobiological Preparations M.P. Chumakova of the Russian Academy of Sciences applied to the Ministry of Health of the Russian Federation for permission to conduct clinical trials of its own vaccine against coronavirus infection. This was announced by the general director of the Chumakov Center, deputy of the Council of Deputies of the Moscow settlement Aidar Ishmukhametov. “Today we have sent all the necessary documents to the Ministry of Health of the Russian Federation to conduct full clinical trials of a vaccine against COVID-19. We are waiting for permission to conduct them and expect to complete clinical trials in October this year. We plan that more than 3 thousand people will take part in the tests, which will meet the requirements of the World Health Organization and other international regulators, ”said the director of the Chumakov center.


10/16/2020 - 09:55